Serological results for these patients noted significantly lower TG, HDL, GGT, ALP, and ALT levels in samples from CLL patients relative to DLBCL patients (P<0.05), suggesting that the metabolic disorders facing DLBCL patients may be more severe such that they face a worse prognosis. The gene discussed is GPT; the disease is diffuse large B-cell lymphoma.